Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naive anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).

被引：0

作者：

Choi, Briana

Alkhatib, Nimer S.

Halawah, Hala

Calamia, Matthias

Gulick, Dexter

Manasrah, AlMothana

Alkhdour, Odai

McBride, Ali

Abraham, Ivo

机构：

[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA

[2] Univ Arizona, Tucson, AZ USA

[3] Al Zaytoonah Univ Jordan, Amman, Jordan

[4] Univ Utrecht, Utrecht, Netherlands

[5] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA

[6] Yarmouk Univ, Fac Med, Irbid, Jordan

[7] Yarmouk Univ, Irbid, Jordan

[8] Univ Arizona, Canc Ctr, Tucson, AZ USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e21102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21102

引用

页数：3